Axal, a blockchain company developing a network of autonomous agents, announced today it has raised $2.5 million in pre-seed funding led by CMT Digital. The funding round also saw participation from ...

This Phase II trial is a “window of opportunity” trial, which was designed to evaluate the effect of AXAL on anti-tumor immunity in the tumor immune microenvironment (TME) of patients with HPVOPC by ...

Three years ago, a small New Jersey biotech called Advaxis was on the brink of ruin. Its cancer drug AXAL was in the middle of clinical trials, but the company was out of money and trading as a penny ...

PRINCETON, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it reached an agreement ...

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ: ADXS) (the Company), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, ...

Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, announced that its lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), has been classified as an ...

Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, announced that it reached an agreement with the US Food and Drug Administration (FDA), under the Special ...

Phase 1 AXAL and durvalumab combination trial shows safety and tolerability in cervical and HPV+ head and neck cancer Preclinical data demonstrate synergistic antitumor effects of AXAL combined with a ...